Return to List
Study Summary
No.
2003-0343:
.......
Brain
......
Amy Heimberger
......
Neurosurgery
.
Study Summary Title
Study Summary
Number:
2003-0343
Study Title:
A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII
.
Physician
New Patient Referral
Name:
Amy Heimberger
Patients Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:
Neurosurgery
Referring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:
713-792-2400
Contact us about clinical trials
.
General Information
Disease Group:
Brain
Supported By:
Goodwin Foundation
Phase of Study:
Phase II
Return
Visit:
Every two weeks for 6 weeks and then monthly until evidence of disease progression.
Treatment
Agents:
Surgical Procedure
Imaging
Collection
rhGM-CSF
PEP-3-KLH
Home Care:
Not applicable
Treatment Loc:
outpatient
Estimated
Length of Stay
in Houston:
Not applicable
Description/
Intervention:
Unavailable
.
Study Objectives / Outcomes
Unavailable
.
Study Status Information
Study Activation / Registration Date:
03/01/2004
IRB Review and Approval Date:
06/04/2003
Study Type:
Cancer Control
Recruitment Status:
Terminated
Projected Accrual:
22
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you.
Please Contact the
Referral Office
for more information.
Inclusion Criteria:
Does the patient have a newly diagnosed, previously untreated GBM?
Histopathology diagnosis of GBM?
A tumor volumetric resection of 95% or greater?
Did the patient sign the approved informed consent?
Exclusion Criteria:
Does the patient have leptomeningeal disease?
.
Links
Registration Number:
NCT00090597
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results
Return to Clinical Trials at M.D. Anderson Cancer Center